(Q44501476)

3 December 2017

title

Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea (English)

1 reference

3 December 2017

0 references

1 reference

1 reference

4

1 reference

3 December 2017

Genton B

1

1 reference

3 December 2017

Al-Yaman F

2

1 reference

3 December 2017

Anders R

3

1 reference

3 December 2017

Brown G

5

1 reference

3 December 2017

Pye D

6

1 reference

3 December 2017

Irving DO

7

1 reference

3 December 2017

Briggs WR

8

1 reference

3 December 2017

Mai A

9

1 reference

3 December 2017

Ginny M

10

1 reference

3 December 2017

Adiguma T

11

1 reference

3 December 2017

Rare L

12

1 reference

3 December 2017

Giddy A

13

1 reference

3 December 2017

Reber-Liske R

14

1 reference

3 December 2017

Stuerchler D

15

1 reference

3 December 2017

Alpers MP

16

1 reference

3 December 2017

language of work or name

English

0 references

publication date

1 May 2000

1 reference

3 December 2017

number of pages

8

1 reference

inferred from page(s)

published in

Vaccine

1 reference

3 December 2017

volume

18

1 reference

3 December 2017

issue

23

1 reference

3 December 2017

page(s)

2504-2511

1 reference

Clinical trials of malaria vaccines: progress and prospects.

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Efficacy trial of malaria vaccine SPf66 in Gambian infants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Evaluation of SPf66 malaria vaccine efficacy in Brazil.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Association between cellular response (IL-4) to RESA/Pf155 and protection from clinical malaria among Papua New Guinean children living in a malaria endemic area

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Humoral response to Plasmodium falciparum ring-infected erythrocyte surface antigen in a highly endemic area of Papua New Guinea

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Structural diversity in the Plasmodium falciparum merozoite surface antigen 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Plasmodium falciparum ring-infected erythrocyte surface antigen is released from merozoite dense granules after erythrocyte invasion

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Malaria: how useful are clinical criteria for improving the diagnosis in a highly endemic area?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. I. Malariometric indices and immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Allelic variants of the Plasmodium falciparum merozoite surface antigen 2 (MSA-2) in a geographically restricted area of Irian Jaya.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Follow-up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. II. Mortality and morbidity.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Relationships between Plasmodium falciparum infection and morbidity in a highly endemic area

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Gamma-globulin and acquired immunity to human malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900036-0

7 January 2021

10.1016/S0264-410X(00)00036-0

Identifiers

DOI

1 reference

3 December 2017

1 reference